Healthcare providers should assess for: Persistent gastrointestinal symptoms that may indicate gallbladder disease Signs of pancreatitis (severe abdominal pain radiating to the back) Changes in vision or symptoms of diabetic retinopathy progression, especially in patients with pre-existing retinopathy Signs of dehydration or acute kidney injury with severe gastrointestinal symptoms Hypoglycemia when used with insulin or sulfonylureas (which may require dose reduction of these medications) Symptoms related to the boxed warning (thyroid tumors): neck mass, hoarseness, dysphagia, or dyspnea Patients should be aware that semaglutide is contraindicated during pregnancy and lactation, and women of childbearing potential should stop treatment approximately 2 months before a planned pregnancy

Steven Heymsfield of Pennington Biomedical Research Center describes the results of the BELIEVE study, which showed that the therapy combination addressed lean mass loss associated with GLP-1-based therapies
(Mechanistic rationale aligns with the literature above.) PMC+1 For longer-term metabolic health, periodically track liver enzymes, lipids, glucose/insulin metrics, and, per standard guidelines, follow age-appropriate bowel cancer screening
When I started my very first dose, I felt drained and tired the next day
Our online weight loss clinic gives you safe access to prescription weight loss injections, like Mounjaro and Wegovy, from experienced healthcare professionals